HK-listed gold stocks jump as US economic fears boost bullion prices
In a turbulent turn of events, Teladoc Inc (NYSE:TDOC)'s stock has tumbled to a 52-week low, touching a price level of just $6.76. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a significant 8.4% decline just this past week. This significant drop underscores a challenging period for the virtual healthcare provider, which has seen its market value erode to $1.29 billion, with a nearly 50% decline over the past year. Investors have been wary of the company's performance amidst increasing competition and concerns over profitability in the telehealth sector, leading to a persistent sell-off that culminated in this week's record low. Despite current challenges, InvestingPro analysis indicates the stock is trading below its Fair Value, with three analysts recently revising their earnings expectations upward for the upcoming period. The market's waning confidence in Teladoc's growth prospects has cast a shadow over the once-booming telemedicine industry, prompting close scrutiny of the company's strategy moving forward. While maintaining a solid gross profit margin of 71%, the company faces profitability challenges, with analysts not expecting positive earnings this year.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings with a revenue of $640.5 million, slightly surpassing the forecast of $638.5 million. However, the company's earnings per share (EPS) of -0.28 missed the expected -0.23, reflecting ongoing challenges in profitability. The full-year revenue for 2024 was $2.6 billion, marking a 1% decline from the previous year. In a strategic move, Teladoc has partnered with Gifthealth, integrating with Eli Lilly (NYSE:LLY)'s LillyDirect to improve access to the medication Zepbound for its Comprehensive Weight Care Program. This partnership aims to enhance the program's marketability by providing a more integrated care approach. Meanwhile, Truist Securities maintained a Hold rating on Teladoc, with a price target of $10.00, while Stifel also reiterated a Hold rating with a $9.00 target, following the company's earnings miss and guidance that fell below market consensus. Additionally, Needham expressed concerns over Teladoc's mixed fourth-quarter results, citing uncertainties regarding the company's growth trajectory and profitability. Despite these challenges, Teladoc remains focused on expanding its international business and stabilizing its BetterHelp segment, which saw a sequential increase in average paying users during the fourth quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.